Download the brochure - 2MB - Updated December 29, 2011
PROGRAM OBJECTIVES
After attending this educational activity, participants will be able to:
- Understand the epidemiology and etiology of lymphomas;
- Describe the epigenetics of lymphoma and how this can be targeted in the treatment of patients with lymphoma;
- Discuss the role of the B-cell receptor both in the biology of lymphoma and also as a therapeutic target;
- Review the microenvironment of lymphoma and how new agents are being developed to disrupt tumor-microenvironmental interactions;
- Understand the role of EBV and other viruses in causing lymphoma;
- Recognize the prognostic tools in DLBCL that help risk-stratify patients;
- Debate new information on the role of observation versus immediate treatment in low-risk follicular lymphoma;
- Review new information on the role of autologous stem cell transplantation as first line consolidation in DLBCL;
- Review the history of treatment in Hodgkin lymphoma and how that guides current therapy;
- Understand the management of cutaneous and peripheral T-cell lymphomas, including the role of transplant.
PROGRAM AGENDA
Friday, April 27, 2012 |
|||
Session Topic |
Time Slot |
Speaker |
Topic |
| 12:00pm | REGISTRATION OPEN | ||
|
1:00-1:10 |
|
Welcome and Introduction |
Session I |
1:10-1:40 |
Brian Chiu, PhD |
The epidemiology of lymphoma: lessons learned |
|
1:40-2:10 |
Susan Bates, MD |
Epigenetics of lymphomas: the basics and the next steps |
Session II |
2:10-2:40 |
Jonathan Friedberg, MD, MMSc |
BCR signaling in lymphoma: relevance and optimal targeting |
|
2:40-3:00 |
Myron Czcuczman, MD |
The microenvironment in lymphoma: is it druggable? |
|
3:00-3:30 |
|
Break |
|
3:30-4:00 |
Richard Longnecker, PhD |
The biology and pathogenesis of EBV-related lymphomas |
SCIENTIFIC KEYNOTE |
4:00-5:00 |
Randy Gascoyne, MD, FRCPC |
Prognostic markers in DLBCL: what is the current standard of care? |
|
5:00-6:15pm |
|
Abstract/poster highlights and wine reception |
| EXHIBITS OPEN: | 1:00–6:00pm | ||
Saturday, April 28, 2012 |
|||
Session Topic |
Time Slot |
Speaker |
Topic |
| 7:00am | REGISTRATION OPEN CONTINENTAL BREAKFAST |
||
|
8:00-8:10 |
|
Welcome and Introduction |
Session I |
8:10-9:10 |
Brian Link, MD (pro) and Christopher Flowers, MD, MS (con) |
Is watch and wait still an appropriate strategy in follicular lymphoma? |
Session II |
9:10-10:00 |
Andrew Evens, DO, MSc; Leo Gordon, MD; Scott Smith, MD, PhD; Chadi Nabhan, MD, FACP |
PTLD and Burkitt’s lymphoma |
|
10:00-10:30 |
|
Break |
Session III |
10:30-11:30 |
Patrick Stiff, MD, ABIM (pro) and Koen Van Besien, MD (con) (Moderator: Timothy Fenske, MD) |
High risk patients with DLBCL should undergo a stem cell transplant as part of front-line treatment |
CLINICAL KEYNOTE |
11:30-12:30 |
Volker Diehl, MD |
Hodgkin lymphoma: historical perspective and future |
|
12:30-1:30 |
|
Lunch |
Session IV EBV Lymphoma |
1:30-2:00 |
Richard Ambinder, MD, PhD |
PTLD and EBV-related lymphomas: novel therapeutic strategies |
Mini-symposium: Spotlight on T-cell Lymphoma |
2:00-2:30 |
Steven Rosen, MD, FACP |
New agents in CTCL: how should they be integrated into overall management? |
|
2:30-3:00 |
Ranjana Advani, MD |
Current front-line approach to PTCL |
|
3:00-3:30 |
Sonali Smith, MD |
Autologous vs. allogeneic stem cell transplant in PTCL |
|
3:30pm |
|
Conference Adjourn |
| EXHIBITS OPEN: | 7:00–2:00pm | ||
Program agenda and speaker selection subject to change.
Page last update: December 29, 2011
